Tetrahydrofolate

Summary

Tetrahydrofolate (CHEMBL2074655) is a phase-3 clinical-stage small molecule; indicated across 1 condition including hyperhomocysteinemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 445.4 Da · C19H23N7O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2074655
Name	Tetrahydrofolate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	135415876
Molecular formula	C19H23N7O6
Molecular weight	445.4
InChIKey	MSTNYGQPCMXVAQ-NEPJUHHUSA-N

SMILES: C1[C@H](NC2=C(N1)N=C(NC2=O)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O

IUPAC name: (2S)-2-[[4-[[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid

Also known as: Tetrahydrofolate, TETRAHYDROFOLATE

Patent coverage: 88,536 distinct patent families (184,047 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 184,034 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hyperhomocysteinemia	1	MONDO:0004743	MONDO:0004743

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).